background
invas
mold
infect
children
hematolog
malign
associ
high
mortal
rate
use
combin
antifung
therapi
case
sever
clinic
cours
increas
although
inform
efficaci
safeti
approach
limit
present
case
seri
children
affect
hematooncolog
disord
receiv
combin
antifung
therapi
invas
mold
infect
center
pediatr
hematolog
san
gerardo
hospit
monza
itali
aim
describ
clinic
characterist
type
infect
treatment
regimen
clinic
outcom
treatment
safeti
medic
record
retrospect
review
order
describ
patient
characterist
result
combin
antifung
therapi
includ
liposom
amphotericin
associ
caspofungin
voriconazol
posaconazol
treatment
respons
rate
patient
show
complet
respons
partial
respons
crude
mortal
half
relat
invas
mold
infect
half
diseas
progress
overal
treatment
well
toler
observ
perman
discontinu
antifung
due
relat
side
effect
conclus
experi
combin
antifung
therapi
seem
safe
option
immunocompromis
children
invas
mold
infect
welldesign
studi
need
confirm
safeti
approach
better
understand
efficaci
pediatr
set
invas
mold
infect
imi
repres
major
caus
morbid
mortal
among
pediatr
patient
affect
hematolog
malign
often
associ
poor
clinic
outcom
despit
use
activ
antifung
drug
controversi
exist
benefit
use
combin
antifung
treatment
cat
patient
popul
particular
attempt
improv
efficaci
treatment
often
balanc
concern
decreas
safeti
due
cumul
toxic
evid
role
cat
treatment
imi
scarc
adult
popul
even
limit
pediatr
set
particular
welldesign
studi
use
cat
immunocompromis
children
lack
current
knowledg
topic
mainli
reli
retrospect
prospect
cohort
scenario
experi
treat
imi
cat
children
may
help
clinician
gain
knowledg
field
hope
serv
start
point
larger
studi
henc
report
reallif
case
seri
use
cat
pediatr
set
present
case
seri
imi
children
affect
hematolog
malign
treat
cat
hematologyoncolog
bone
marrow
transplant
unit
pediatr
depart
san
gerardo
hospit
monza
itali
aim
describ
clinic
characterist
type
infect
clinic
outcom
treatment
safeti
patient
diagnosi
possibl
probabl
proven
imi
defin
european
organ
research
treatment
cancer
eortc
criteria
includ
medic
record
retrospect
review
describ
patient
characterist
outcom
treatment
safeti
patient
record
clinic
outcom
week
diagnosi
imi
among
live
patient
distinguish
complet
respons
treatment
full
recoveri
partial
respons
major
improv
symptom
radiolog
find
studi
period
case
imi
pediatr
patient
affect
hematolog
malign
treat
cat
center
eight
patient
male
mean
age
year
year
demograph
characterist
patient
see
tabl
five
patient
met
eortc
criteria
proven
imi
particular
absidia
corymbifera
anoth
untyp
mucoral
grew
orbit
biopsi
patient
rhinoorbitalcerebr
mucormycosi
aspergillu
flavu
grew
orbit
biopsi
patient
rhinocerebr
pulmonari
aspergillosi
fusarium
subglutinan
isol
blood
cultur
fourth
patient
dissemin
fusariosi
cutan
involv
fifth
patient
hypha
liver
biopsi
establish
diagnosi
proven
imi
probabl
aspergillosi
result
cultur
avail
hepatosplen
pulmonari
involv
five
patient
probabl
pulmonari
aspergillosi
document
galactomannan
antigen
assay
compat
clinicalradiolog
sign
patient
pulmonari
diseas
also
central
nervou
system
cn
involv
liver
involv
remain
patient
possibl
pulmonari
aspergillosi
also
hepatosplen
involv
note
diagnosi
probabl
possibl
hepatosplen
involv
establish
imag
characterist
imi
summaris
tabl
ten
patient
develop
imi
receiv
chemotherapi
follow
hematopoiet
stem
cell
transplant
hsct
among
patient
receiv
chemotherapi
affect
acut
lymphoblast
leukemia
frontlin
therapi
firstrelaps
affect
firstrelaps
acut
myeloid
leukemia
aml
firstrelaps
nonhodgkin
lymphoma
nhl
haemophagocit
lymphohistiocytosi
hlh
frontlin
treatment
intens
phase
chemotherapi
induct
reinduct
phase
essenti
anthracyclin
vincristin
steroid
antimetabolit
alkyl
agent
second
group
patient
receiv
hsct
relaps
nhl
relaps
chronic
myeloid
leukemia
receiv
myeloabl
condit
regimen
one
patient
liver
graftversushostdiseas
receiv
treatment
cyclosporin
mycophenol
steroid
patient
neutropen
time
diagnosi
imi
particular
patient
neutrophil
count
patient
neutrophil
count
within
patient
within
sever
neutropenia
defin
neutrophil
count
mm
preced
diagnosi
imi
last
averag
day
day
moreov
patient
receiv
steroid
prednisolon
dexamethason
methylprednisolon
receiv
high
dose
prednison
equival
transplant
patient
also
undergo
prophylaxi
cyclosporin
accord
intern
guidelin
patient
receiv
antifung
prophylaxi
highrisk
underli
diseas
liposom
amphotericin
lamb
fluconazol
one
posaconazol
characterist
hematolog
malign
summaris
tabl
treatment
ten
patient
receiv
cat
salvag
treatment
remain
receiv
cat
firstlin
approach
latter
group
undergo
prophylaxi
lamb
twice
weekli
one
fluconazol
mgkgdaili
diagnosi
imi
establish
combin
regimen
includ
lamb
associ
caspofungin
posaconazol
voriconazol
ten
patient
receiv
lamb
mgkg
daili
patient
cn
involv
receiv
mgkgdaili
caspofungin
use
dosag
dosag
posaconazol
voriconazol
titrat
accord
plasmat
concentr
therapeut
drug
monitor
tdm
caspofungin
chosen
second
antifung
agent
patient
invas
aspergillosi
ia
posaconazol
given
patient
rhinoorbitalcerebr
mucormycosi
patient
possibl
ia
alreadi
receiv
lamb
prophylaxi
voriconazol
chosen
second
agent
patient
cn
aspergillosi
patient
pulmonari
aspergillosi
patient
invas
fusariosisth
mean
durat
cat
day
day
maxillofaci
surgeri
requir
case
rhinoorbitalcerebr
mucormycosi
aspergillosi
treatment
see
tabl
record
outcom
week
diagnosi
imi
overal
mortal
two
death
relat
progress
cn
aspergillosi
progress
underli
malign
overal
respons
patient
show
complet
respons
one
report
monocular
blind
surgic
curettag
orbit
show
partial
respons
see
tabl
toxic
cat
classifi
accord
common
terminolog
criteria
advers
event
overal
cat
well
toler
seven
patient
report
transitori
alter
liver
test
includ
bilirubin
transaminas
gammaglutamyltransferas
ggt
particular
patient
report
grade
increas
liver
marker
ggt
one
transaminas
patient
report
grade
increas
bilirubin
also
report
grade
increas
ggt
report
grade
increas
transaminas
remain
patient
report
grade
increas
ggt
also
report
grade
increas
transaminas
moreov
patient
report
acut
kidney
injuri
aki
hypokalemia
marker
liver
dysfunct
high
patient
treat
combin
lamb
voriconazol
patient
treat
combin
lamb
caspofungin
note
among
patient
also
hepat
involv
fungal
infect
case
aki
led
lamb
dose
reduct
anoth
patient
alter
liver
test
led
temporari
discontinu
cat
safe
reintroduc
hour
later
improv
hepat
function
definit
discontinu
occur
see
tabl
abbrevi
lamb
liposom
amphotericin
b
aki
acut
kidney
injuri
cat
combin
antifung
therapi
despit
improv
outcom
imi
children
hematolog
malign
report
recent
studi
compar
studi
last
decad
mortal
still
high
patient
popul
particular
recent
studi
children
hematooncolog
disord
imi
treat
differ
regimen
report
crude
mortal
rate
rang
line
case
seri
overal
death
rate
cat
often
chosen
strategi
improv
outcom
case
imi
sever
clinic
cours
main
goal
widen
spectrum
therapi
lower
risk
resist
exploit
synerg
drug
random
control
studi
publish
adult
patient
assess
role
cat
compar
monotherapi
clinic
set
still
littl
evid
efficaci
safeti
approach
evid
limit
adult
popul
even
scarcer
pediatr
set
infecti
diseas
societi
america
idsa
european
societi
clinic
microbiolog
infecti
diseas
escmid
guidelin
still
recommend
monotherapi
major
imi
combin
therapi
echinocandin
lamb
azol
list
altern
salvag
therapi
ia
associ
lamb
posaconazol
caspofungin
regard
option
refractori
mucormycosi
despit
lack
welldesign
trial
assess
efficaci
safeti
approach
combin
antifung
regimen
wide
use
reallif
pediatr
set
report
sever
studi
monocentr
survey
imi
immunocompromis
children
report
use
combin
therapi
percentag
case
rang
multicent
cohort
studi
perform
burgo
et
al
involv
us
pediatr
center
report
use
combin
regimen
imi
moreov
multicent
intern
prospect
cohort
studi
mucormycosi
pana
et
al
report
use
firstlin
combin
therapi
case
similar
find
sever
pediatr
seri
report
use
cat
mainli
salvag
treatment
also
firstlin
especi
patient
receiv
antimold
prophylaxi
recent
italian
multicent
studi
invas
fungal
infect
hematooncolog
pediatr
patient
episod
treat
antifung
combin
initi
therapi
author
specul
choic
driven
sever
clinic
condit
patient
furthermor
intern
multicent
observ
cohort
studi
wattier
et
al
imi
children
affect
hematolog
neoplasm
firstlin
combin
therapi
use
case
similar
find
mainli
use
patient
alreadi
receiv
antimold
prophylaxi
possibl
due
concern
prophylaxisinduc
resist
overal
respons
combin
therapi
case
seri
imi
associ
mortal
definit
discontinu
relat
toxic
occur
data
pediatr
literatur
cat
report
similar
rate
favor
respons
toxic
although
heterogen
patient
popul
antifung
regimen
studi
togeth
differ
underli
neoplasm
fungal
infect
includ
prevent
draw
evid
superior
cat
monotherapi
relat
outcom
safeti
inde
outcom
report
case
seri
differ
outcom
report
literatur
children
treat
monotherapi
overal
pauciti
welldesign
studi
aim
compar
mortal
pediatr
patient
treat
monotherapi
versu
combin
therapi
particular
prospect
studi
wattier
et
al
compar
outcom
safeti
children
imi
ia
treat
cat
monotherapi
studi
favor
associ
cat
outcom
found
convers
cat
associ
increas
toxic
howev
studi
sever
limit
inde
acknowledg
author
particular
heterogen
cat
furthermor
ineffect
cat
outcom
hamper
sever
confound
factor
sever
ill
patient
like
receiv
aggress
therapi
also
like
experi
poor
outcom
associ
cat
toxic
could
result
underli
sever
ill
center
combin
lamb
caspofungin
use
ia
main
cat
combin
synerg
vitro
show
promis
clinic
result
among
adult
children
patient
treat
associ
surviv
fifth
die
due
progress
underli
malign
note
patient
one
group
aspergillosi
rhinocerebr
involv
conflict
result
avail
literatur
associ
lamb
azol
vitro
studi
report
antagon
drug
combin
proven
effect
associ
improv
outcom
anim
model
cn
aspergillosi
although
evid
controversi
mani
reallif
studi
report
use
combin
clinic
practic
pediatr
set
case
seri
combin
lamb
voriconazol
mainli
use
treat
cn
aspergillosi
among
patient
mortal
rate
high
note
cn
aspergillosi
histor
associ
poor
outcom
studi
need
establish
best
treatment
intrins
resist
fusarium
speci
antifung
lead
high
mortal
rate
patient
invas
fusariosi
despit
concern
vitro
antagon
polyen
azol
studi
shown
vitro
synerg
voriconazol
lamb
fusarium
base
studi
clinic
report
success
treatment
invas
fusariosi
associ
lamb
voriconazol
author
support
cat
fusariosi
case
seri
patient
invas
fusariosi
success
treat
lamb
associ
voriconazol
lastli
associ
lamb
caspofungin
posaconazol
associ
encourag
result
salvag
treatment
mucormycosi
describ
case
mucormycosi
rhinocerebr
orbit
involv
success
treat
lamb
associ
posaconazol
surgeri
recent
studi
greec
pana
et
al
report
use
cat
children
invas
mucormycosi
howev
impact
cat
surviv
could
estim
due
small
patient
popul
present
age
case
imi
immunocompromis
children
affect
hematolog
malign
still
associ
high
morbid
mortal
case
seri
report
reallif
experi
treat
imi
cat
pediatr
center
given
mere
descript
purpos
report
lack
statist
analysi
awar
work
provid
enough
evid
recommend
efficaci
safeti
cat
children
hematooncolog
malign
affect
imi
howev
given
scarciti
data
topic
literatur
togeth
rariti
infect
patient
popul
yet
associ
sever
prognosi
believ
even
isol
experi
singlecent
institut
add
use
knowledg
field
wait
welldesign
control
studi
cat
might
regard
possibl
approach
imi
children
hematooncolog
diseas
particular
use
cat
could
consid
earli
prognosi
favor
studi
perform
accord
declar
helsinki
parentalguardian
inform
consent
previous
approv
ethic
committe
obtain
patient
use
anonym
data
research
purpos
public
